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Abstract
Aggregated α-synuclein and the point mutations Ala30Pro and Ala53Thr of α-synuclein are
associated with Parkinson’s disease. The physiological roles of α-synuclein and methionine
oxidation of the α-synuclein protein structure and function are not fully understood. Methionine
sulfoxide reductase A (MsrA) reduces methionine sulfoxide residues and functions as an
antioxidant. To monitor the effect of methionine oxidation to α-synuclein on basic cellular
processes, α-synucleins were expressed in msrA null mutant and wild-type yeast cells. Protein
degradation was inhibited in the α-synuclein-expressing msrA null mutant cells compared to α-
synuclein-expressing wild-type cells. Increased inhibition of degradation and elevated
accumulations of fibrillated proteins were observed in SynA30P-expressing msrA null mutant
cells. Additionally, methionine oxidation inhibited α-synuclein phosphorylation in yeast cells and
in vitro by casein kinase 2. Thus, a compromised MsrA function combined with α-synuclein
overexpression may promote processes leading to synucleinopathies.
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Introduction
One of the hallmarks of Parkinson’s disease (PD) is the formation of Lewy bodies (Lucking
and Brice 2000). These neuronal inclusion bodies are composed of aggregated proteins and
consist mainly of α-synuclein fibrils (Baba et al. 1998). The α-synuclein protein is a
presynaptic protein of unknown function and its involvement in the pathogenesis of PD is
still not clear. However, the α-synuclein point mutations Ala30Pro and Ala53Thr are found
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in autosomal dominant forms of PD (Kruger et al. 1998; Polymeropoulos et al. 1997).
Overexpression of α-synuclein is also associated with the risk of developing PD (Takeda et
al. 1998), and α-synuclein locus triplication can cause PD (Singleton et al. 2003). When α-
synuclein is abnormally expressed or modified, various studies indicate that it may cause
alterations in mitochondrial and proteasomal function, protein aggregation, and
accumulation of reactive oxygen species (ROS; Lindersson et al. 2004; Sawada et al. 2004;
Snyder et al. 2005; Vekrellis et al. 2004).
Yeast cells have been used to study events related to α-synuclein biology and toxicity. This
toxicity was shown to be mediated by increased cellular ROS and decreased proteasome
function (Chen et al. 2004; Sharma et al. 2006; Willingham et al. 2003). The monomeric α-
synuclein forms fibrils at a relatively slow rate. We hypothesize that modifications alter the
physical properties and degradation rate of α-synuclein, overall promoting its
oligomerization. This is consistent with the associated increase in oxidative stress among
PD, aging, and other neurodegenerative diseases. Increased ROS and cellular α-synuclein
levels promote its aggregation (Giasson et al. 2000; Hsu et al. 2000). The presence of ROS
can cause posttranslational modifications, commonly to the sulfur-containing residues
methionine (Met) and cysteine (Cys). The α-synuclein protein does not have Cys, but does
contain four Met residues that can be readily oxidized to Met sulfoxide (MetO) in vitro.
Under conditions of oxidative stress, MetO-α-synuclein can form fibrils when triggered by
certain metals (e.g., Zn2+, Al3+, etc.) in vitro (Yamin et al. 2003). Furthermore, cellular
conditions such as higher α-synuclein protein concentrations (Fink 2006) and a saline
environment (Munishkina et al. 2004) could increase the rate of α-synuclein fibril
formation. Posttranslational modifications can alter the solubility of α-synuclein, possibly
decreasing the clearance of this short-lived protein. Cytoplasmic α-synuclein can be
degraded by the ubiquitin–proteasome system, the autophagy system, and lysosomic
pathway (Giorgi et al. 2006); however, degradation of α-synuclein is inhibited in PD. It is
plausible that the latter inhibition decreases the clearance and promotes aggregation of α-
synuclein. Modifications to α-synuclein may alter its solubility and interfere with its ability
to be degraded, thereby resulting in a decreased clearance of α-synuclein.
The MetO modifications formed in the presence of ROS produce the enantiomers Met-S-O
and Met-R-O. In proteins, MetO is reduced solely by Msr enzymes, which are MsrA
(reduces Met-S-O) and MsrB (reduces Met-R-O; Moskovitz 2005; Oien and Moskovitz
2008). However, MsrA is thought to be the major Msr because it positively regulates MsrB
expression (Moskovitz 2007; Moskovitz and Stadtman 2003). Lack of MsrA has been
demonstrated in several organisms to cause a hypersensitivity to oxidative stress conditions
(Oien et al. 2008; Pal et al. 2007) and premature death (Moskovitz et al. 2001; Oien and
Moskovitz 2007). In contrast, overexpression of msrA may suppress dopaminergic cell
death and protein aggregation (Liu et al. 2008). One hypothesis to explain the late onset of
certain neurodegenerative diseases, such as PD, is that they occur in aging neurons when the
capacity of the quality control system to cope with accumulating misfolded proteins is
exceeded (Berke and Paulson 2003). This situation has been modeled in yeast by increasing
α-synuclein expression (Outeiro and Lindquist 2003). Due to the lack of substantial
information about MetO-α-synuclein in vivo, we further explored this by overexpressing α-
synuclein and two mutants in msrA null (msrA-KO) yeast cells. The effects of the α-
synucleins on protein fibril formation, degradation, and phosphorylation were monitored.
Materials and Methods
Overexpressing Human α-Synuclein in Yeast
The human α-synuclein protein and its mutants were overexpressed in msrA-KO and WT
Saccharomyces cerevisiae strains with the pYES6 expression vector used previously
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(Moskovitz et al. 1997). This vector harbors the yeast GAL1 promoter for high-level
inducible protein expression by galactose. It has a C-terminal peptide encoding a V5 epitope
and a polyhistidine (6His) tag for detection and purification of the recombinant fusion α-
synuclein. This vector contains the ampicillin and blasticidin resistance genes for selection
of bacteria and yeast colonies harboring the plasmid, respectively. Three forms of the human
α-synuclein cDNA (wild type (α-synuclein), Ala53Thr (SynA53T), and Ala30Pro
(SynA30P)) were inserted into the vector keeping the sequence in frame with the 6His
peptide. For that purpose, suitable 5′ forward and 3′ reverse complement primers (harboring
Hind III and Xba I restriction sites, respectively) were used with each of the α-synuclein
cDNAs (kindly provided by Dr. Mikiei Tanaka, NIH, NHLBI) in a routine polymerase chain
reaction (PCR) procedure. The resulting PCR products were subcloned into the suitable
complementary restriction sites on the pYES6 and transformed into bacterial cells (DH5α).
Each plasmid was isolated from bacterial cells and transformed into WT and msrA-KO
yeast. Vector-only transformed cells served as controls. Following growth selection on
media containing blasticidin (Invivogen), all the transformed yeast strains (WT and msrA-
KO containing either the vector only, vector containing α-synuclein, or vector containing
either SynA53T or SynA30P) were grown in induction media containing 2% galactose and
1% raffinose for up to 24 h. At various time points, equal amounts of cells were taken from
each culture (determined by optical density (OD600nm)) and extracted by glass beads and a
bead-beater homogenizer apparatus (BioSpec Products, Bartlesville, OK, USA). The α-
synuclein proteins were purified from the corresponding extracts by using of ProBond™
Nickel-Chelating Resin (Invitrogen). Equal volumes of purified α-synuclein proteins were
subjected to sodium dodecyl sulfate (SDS)-gel electrophoresis and detected by Western
blotting using anti-6His antibodies (Immunology Consultants Laboratories).
Total Protein Degradation and Synthesis in Yeast Expressing α-Synuclein
The procedure was performed as done previously (Chen et al. 2005) with modifications.
Yeast cells (WT and msrA-KO) expressing the three α-synuclein variants (α-synuclein,
SynA30P, SynA53T) were grown in yeast extract–peptone–dextrose (YPD; Fisher
Scientific) medium to midlogarithmic phase while shaking at 30°C. The medium was
removed by centrifugation and replaced with 2% galactose and 1% raffinose media lacking
Met. Next, 50µCi [35S]Met (Perkin-Elmer) was added and incubated for additional 30 min.
The medium was removed and radioactive labeling was chased by media containing Met
without radioactive isotopes. At different time intervals, equal aliquots of cells were
removed from each culture and homogenized. The corresponding protein extracts were
mixed with trichloroacetic acid (TCA) at a final concentration of 20% (v/v). After
incubation at 4°C for 1 h, the samples were centrifuged, and the radioactivity (counts per
minute) of the TCA-insoluble precipitates and soluble material was measured by liquid
scintillation counting. For quantification of protein synthesis, the radioactivity (counts per
minute) of the TCA-insoluble precipitate was measured by liquid scintillation counting after
labeling with 50µCi [35S]Met and immediate precipitation with TCA.
Phosphorylation of α-Synuclein in Yeast (Ex Vivo System)
The WT and msrA-KO yeast cells expressing α-synuclein, SynA30P, and SynA53T were
grown in YPD medium to midlogarithmic phase shaking at 30°C. The medium was removed
by centrifugation and substituted with induction media containing 2% galactose and 1%
raffinose for 1 h. The cells were then incubated in media with only 10% of the nutrients for
1 h to reduce free phosphate. To each culture, 5µCi/mL [32P]orthophosphoric acid (Perkin-
Elmer) was added and incubated for 1 h. The cells were harvested and α-synuclein was
isolated by resin affinity as described above with the addition of NaF and Na2VO4 as
phosphatase inhibitors. The α-synuclein was eluted from the resin with 150 mM imidazole.
Equal amounts of each eluted protein were subjected to an SDS-gel electrophoresis. At the
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end of electrophoretic separation, the gel was stained with Gel-Code Blue (Thermo
Scientific, Rockford, IL, USA). Bands corresponding to the molecular weight of the α-
synucleins were excised, added to vials with liquid scintillation cocktail, and their counts per
minute measurements were determined by liquid scintillation counting.
Phosphorylation of α-Synuclein In Vitro
Recombinant α-synuclein, SynA30P, and SynA53T (rPeptide) were incubated overnight in
200 mM H2O2 at 37°C in phosphate buffered saline buffer. The H2O2 was removed by
adding catalase and incubating 30 min (oxidant removal verified by adding α-synuclein
after oxidants were removed, this served as the nonoxidized α-synuclein control). To reduce
MetO, recombinant yeast MsrA and PilB were produced as previously described (Moskovitz
et al. 1997; Olry et al. 2002). These Msrs were added at a concentration of 0.3 mg/mL with
20 mM dithiothreitol for 1 h. Each α-synuclein was phosphorylated by adding 6 mCi
[γ-32P]-ATP (Perkin-Elmer), 20µM cold ATP, 10 mM MgCl2, and 0.3 µg casein kinase 2
(Upstate) for 1 h. Reactions were stopped by adding an equal volume of protein gel sample
buffer. Equal amounts of α-synuclein proteins were subjected to an SDS-gel electrophoresis.
At the end of the electrophoretic separation, the gel was stained with Gel-Code Blue Stain
reagent and exposed to X-ray film.
Protein Fibrillation in Yeast Strains Expressing α-Synuclein
In the presence of fibrils, Thioflavin T undergoes a “red shift” where it is excited at a
wavelength of 442 nm and emits fluorescence at 482 nm. Yeast cells were grown in YPD
and incubated in media with 2% galactose and 1% raffinose for 3 h. The cells were
precipitated by centrifugation and resuspended in 1% Thioflavin T solution. Cells were
washed in buffer and aliquots were diluted into a 96-well plate. Finally, Thioflavin T
fluorescence was imaged and quantified using an IN Cell Analyzer 1000 (GE Healthcare)
high content imaging system.
Statistics
Comparison and calculation of P values was performed using Student t test analysis. Values
of P<0.05 were considered significant.
Results and Discussion
Overexpression of α-Synuclein in Yeast
To investigate the effects of MetO on α-synuclein and its point mutation variants (α-
synuclein, SynA30P, SynA53T), they were separately overexpressed in WT or msrA-KO
yeast cells. Cell aliquots were collected at various time points during the expression period
of the α-synuclein proteins. Following conditional α-synuclein purification from the yeast
cells, bands migrating at ~22 and ~16 kDa positions were detected by Western blot analysis
(Fig. 1). The 22-kDa band corresponds to the full length of α-synuclein with the 6His tag
moiety, which is known to cause slower migration in gel electrophoresis due to the added
mass and positive charge. Accordingly, the 16-kDa and lower detected minor bands
correspond to degradation products of the 22-kDa band. The three types of α-synuclein are
degraded at an increased rate when expressed in the WT compared to the msrA-KO strain.
The time-dependent degradation of the corresponding α-synucleins is trailing in the msrA-
KO relative to WT strain without complete degradation of the 16-kDa band, which is
completely degraded in WT strain (Fig. 1). Moreover, among all the types of α-synuclein
examined, the SynA53T type seems to be the most resistant to degradation in the WT strain
while the SynA30P appears to be the most resistant to degradation in the msrA-KO strain
(Fig. 1). Interestingly, the degradation of the SynA30P into both the 16-kDA peptide and
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lower mass peptides was inhibited more in the msrA-KO strain as shown by the relative
lower amounts of the shorter peptides products with time (Fig. 1). The antibodies used in the
Western blot recognize only α-synuclein protein and derived peptides that still contain the
6His tag, which provides recognition that is not based on α-synuclein conformation.
The expression patterns of α-synuclein suggests that the three types of α-synuclein are
degraded faster in the WT compared to the msrA-KO strain (Fig. 1). Moreover, the
SynA30P variant of α-synuclein was the most resistant to degradation in the msrA-KO
strain (Fig. 1). This result is supported by previous studies showing that WT yeast cells
overexpressing SynA30P are inhibited in their general protein degradation by the
proteasome, compared to non-mutated α-synuclein (Chen et al. 2005). We suggest that the
degradation of α-synuclein is inhibited more in msrA-KO cells compared to WT cells,
which may be an enhanced inhibitory effect of the MetO on cellular degradation. Using
matrix-assisted laser desorption/ionization-mass spectrometry (MALDI-MS) techniques, we
have verified that SynA30P and SynA53T expressed in the msrA-KO cells had elevated
levels of Met oxidation relative to same α-synucleins expressed in WT cells (data not
shown).
Protein Degradation and Synthesis in Yeast Strains Overexpressing α-Synuclein
The accumulation of α-synuclein may be causing a general inhibition of degradation
processes that is increased in the msrA-KO strain. Following pulse-chase labeling with [35S]
Met during the induction period of α-synuclein synthesis, all types of expressed α-synuclein
lowered the percentage levels of acid-soluble labeled material, mostly in msrA-KO cells
(Fig. 2a; labeled acid-soluble material, soluble degradation products; and labeled nonsoluble
material, newly synthesized proteins; represent total labeled proteins). While SynA53T was
the only type having a significant reduction effect on the WT total protein degradation rate,
all types of α-synuclein reduced the total degradation rate in the msrA-KO strain compared
to control (Fig. 2a).
It is noteworthy that the degradation rate over time was elevated in the msrA-KO versus WT
yeast strain when sham vector was present. One possible explanation is that accumulation of
MetO-containing proteins (the case in the msrA-KO strain) induces the action of the
degradation machinery as an attempt to remove the faulty proteins (Stadtman and Berlett
1998). However, this response is inhibited by excess levels of specific α-synuclein types
(Figs. 1 and 2a). The general inhibition of protein degradation was more pronounced in the
msrA-KO cells expressing native and A30P α-synucleins (Fig. 2a). The overexpressed
native α-synuclein effect on cellular degradation may be relevant to its accumulation that is
thought to be a risk factor for PD, and specifically impaired α-synuclein degradation may be
involved (Singleton et al. 2003).
The mechanism by which the nature of α-synuclein and MetO modifications to α-
synucleins inhibits degradation is not known. The degradation pathways may be inhibited by
the cellular localization of α-synuclein. In yeast, each α-synuclein mutant accumulated at
the same level as non-mutated α-synuclein, but the cellular distributions differed
profoundly. Similar to native α-synuclein, SynA53T is concentrated at the plasma
membrane, while SynA30P dispersed throughout the cytoplasm (Brandis et al. 2006; Bussell
and Eliezer 2003; Jo et al. 2002). Therefore, the cytoplasmic localization of SynA30P may
cause the protein to be more prone to oxidation (compared to a membrane region) and
accordingly less protected from the accumulation of MetO in the absence of cytoplasmic
MsrA. This may also partly explain the special negative effect of MetO-α-synuclein
accumulations on cytoplasmic degradation, as accumulations of oxidized proteins can inhibit
protein degradation (Starke-Reed and Oliver 1989).
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Inhibition of protein synthesis by native and Ala30Pro α-synuclein expressed in yeast cells
was previously described (Chen et al. 2005). Therefore, we examined the contribution of
msrA ablation to the α-synuclein inhibitory effect on protein synthesis. Expression of α-
synuclein caused an overall inhibition of protein synthesis in both strains compared to
control cells expressing the sham vector (Fig. 2b). The inhibition levels were similar in both
yeast strains expressing either SynA30P or SynA53T. However, a combination of msrA
ablation and native α-synuclein expression in msrA-KO cells caused a stronger inhibitory
effect on protein synthesis compared to WT cells expressing native α-synuclein (Fig. 2b).
As discussed by other groups (Chen et al. 2005), the basis for decreased protein synthesis in
cells expressing α-synuclein is unknown. They suggest that the impairments in this
synthesis may either represent negative feedback (result of impaired protein degradation) or
α-synuclein induction of endoplasmic reticulum stress impairing protein synthesis (Chen et
al. 2005). It is possible that alterations to the structure and function of native α-synuclein
expressed in msrA-KO cells are more effective in fostering inhibition of protein synthesis
(Fig. 2b).
Accumulation of Fibrillated Proteins in Yeast Strains Overexpressing α-Synuclein
Fibrillation of protein, in general, and α-synuclein, in particular, is associated with
posttranslational or genetic modifications to a protein. The observations above, suggesting
an inhibition of degradation and accumulation of oxidized protein in cells expressing α-
synuclein, led us to examine the contribution of these events to α-synuclein-mediated fibril
formation. Yeast cells were stained with Thioflavin T, which is commonly used for
detection of fibrillated proteins (Hawe et al. 2008). Cells were imaged by phase-contrast
microscopy, and the staining of protein fibrils was detected with epifluorescence (Fig. 3a).
In addition, quantification of stained cells per amount of cells present was determined (Fig.
3b). Expression of native α-synuclein in the WT strain had no effect on the percentile of
cells exhibiting protein fibrillation compared to the sham vector. However, expression of
SynA30P and, to a lower extent, SynA53T increased the percentile of cells containing
protein fibrillation. Additionally, the msrA-KO strain shows an increased effect on protein
fibrillation over the WT values when SynA30P is expressed and, to a lower extent, when
native α-synuclein is expressed. In contrast, SynA53T expression had similar effect on the
induction of protein fibrillation in both WT and msrA-KO strains. In general, it appears that
expression of α-synuclein either with point mutations or in the absence of MsrA causes
protein fibrillation.
Several posttranslational modifications can alter the solubility of α-synuclein. Oxidation
will cause a Met residue to be more hydrophilic, but the overall MetO-protein may become
more hydrophobic by exposing hidden hydrophobic residues (Chao et al. 1997). Degradation
of α-synuclein is inhibited in PD, and thus, it is a plausible theory that this inhibition (also
shown in Figs. 1 and 2) decreases the clearance of α-synuclein and promotes its
aggregation, especially when the protein undergoes modifications that reduce its solubility.
All types of α-synuclein caused enhanced cellular fibrillation in the absence of MsrA
compared to the vector, while SynA30P had the most effect on forming fibrils in the msrA-
KO strain (Fig. 3). This result would be the expected outcome of enhanced inhibited
degradation of the α-synuclein A30P (Figs. 1 and 2). Since the SynA53T aggregation is less
affected by the presence of MsrA (Fig. 3), it may reflect the enhanced aggregation found in
PD patients carrying this mutation (Lee et al. 2002; Ostrerova-Golts et al. 2000). However, a
combination of a compromised Msr system (from mutations or lowered expression with age)
and overexpression of SynA30P could cause even greater levels of α-synuclein fibrils in PD
patients.
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Phosphorylation of α-Synuclein and Its Dependency on Methionine Sulfoxide Reductase
The functional role of phosphorylation to α-synuclein is not fully understood. Given our
new data, it was intriguing to determine whether oxidation of Met could also affect the
phosphorylation efficiency of α-synuclein. To follow the phosphorylation efficiency in both
yeast strains expressing α-synuclein types, [32P]ortho-phosphate was included in the
expression induction media. Following the induction, the three types of α-synuclein protein
were isolated from the corresponding yeast strains and phosphorylation was quantified by
measuring the radiolabeling of the protein. All α-synuclein types isolated from msrA-KO
cells showed significantly lower levels of phosphorylation relative to α-synuclein isolated
from WT cells, especially in the native α-synuclein and SynA30P (Fig. 4a). The overall
phosphorylation rate of SynA53T was significantly lower in both yeast strains, which may
imply that this form of α-synuclein is more prone to oxidation even under normal function
of the Msr system. Lower in vivo phosphorylation levels of α-synuclein in msrA-KO cells
suggest that increased levels of MetO moiety in msrA-KO cells could partly inhibit the
phosphorylation efficiency of α-synuclein. The two types of α-synuclein that are mostly
affected by this phosphorylation decline in the msrA-KO strain are the native α-synuclein
and SynA30P, similar to the effect of msrA-KO strain on protein fibrillation in the presence
of these α-synuclein types (Fig. 3).
To further investigate the possibility that methionine oxidation of α-synuclein may
contribute to the phosphorylation inhibition, we used recombinant α-synuclein proteins in
reduced and oxidized form, [32P]ATP, and casein kinase 2 (a major kinase for α-synuclein
Ser129 phosphorylation; Ishii et al. 2007). To confirm that MetO formed in the oxidized α-
synuclein is responsible for the observed effect on phosphorylation level, MsrA and PilB
(naturally fused MsrA–MsrB protein from Neisseria gonorrhoeae) were added to the
reaction mixture to reduce α-synuclein MetO residues. All samples were subjected to SDS-
gel electrophoresis, gels were stained with GelCode Blue Stain (Fig. 4b), and
phosphorylation was visualized by autoradiography. The oxidation of the three types of α-
synuclein inhibited the phosphorylation by casein kinase 2 (Fig. 4c), while both MsrA and
PilB were able to reverse this inhibition via MetO reduction. Both of the mutant α-synuclein
proteins were more phosphorylated when reduced by the Msr enzymes (Fig. 4c). Thus, it is
possible that conformational changes that may occur in these α-synuclein mutants may also
facilitate MetO reduction by the Msr system due to better accessibility of the enzyme to
MetO residues. It is important to note that casein kinase 2 phosphorylation activities on
control samples were not altered when Msr enzymes were added. This excludes the
possibility that the enhanced α-synuclein phosphorylation, shown by Msr enzymes, is due to
their reducing activity on casein kinase 2. Also, using MALDI-MS, we have verified that the
recombinant α-synucleins had elevated levels of oxidation relative to nonoxidized and Msr-
reduced α-synucleins (data not shown).
The role of phosphorylation of α-synuclein (especially at Ser129) is controversial. The
phosphorylation α-synuclein at Ser129 by casein kinase 2 forms fibrils faster than
unmodified α-synuclein in vitro (Fujiwara et al. 2002) and increases the formation of
cytoplasmic inclusion bodies in cell culture models of synucleinopathies (Smith et al. 2005).
However, in vivo studies showed no obvious correlation between phosphorylated Ser129 and
of α-synuclein fibril formation (Chen and Feany 2005). In contrast, another study
demonstrated that phosphorylation at Ser129 inhibits α-synuclein fibril formation in vitro
(Paleologou et al. 2008). With regard to the vicinity of Met127 to Ser129, we have examined
the effect of MetO modifications on the rate of the in vivo phosphorylation of α-synuclein
and casein kinase 2-mediated phosphorylation of α-synuclein. The observed decrease in α-
synuclein phosphorylation due to MetO following MsrA ablation in cells (Fig. 4a) may be
relevant to processes that regulate α-synuclein phosphorylation. As the provided yeast
system is only a model to investigate the role of MsrA in maintaining α-synuclein function,
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further investigations in a parallel mammalian system will greatly contribute to clarify the
physiological role of MsrA on α-synuclein phosphorylation.
A functional Msr system and Met oxidation may have a role in regulating α-synuclein and
the phosphorylation of other proteins. Recent studies suggested that MetO formation on
inhibitory factor of nuclear factor-kappaB (IkBα) prevents its subsequent degradation.
Similar to α-synuclein, the IkBα Met45 residue is close to the phosphorylation sites Ser32
and Ser36. The MetO formation, particularly within helices, can cause major conformational
rearrangements (Bigelow and Squier 2005), and the oxidation of Met45 may cause a
structural disruption that makes the protein a less effective kinase target (Kanayama et al.
2002; Midwinter et al. 2006; Mohri et al. 2002). In another recent study, MsrA was shown
to suppress dopaminergic protein aggregation induced by mutant α-synuclein via MetO
repair. The MsrA was able to reduce several oxidized Met residues in recombinant α-
synuclein (Liu et al. 2008). Overall, it is suggested that oxidation of Met in α-synuclein
inhibits phosphorylation, which may be involved in processes relevant to its degradation or
aggregation depending on cellular environment.
In summary, both the nature of α-synuclein and presence of MsrA determined the overall
protein and α-synuclein degradation in yeast. Furthermore, Met oxidation of α-synuclein
inhibits α-synuclein phosphorylation. This occurs parallel to increasing protein fibrillation,
especially when SynA30P is expressed in msrA-KO cells. To establish the relationships
between α-synuclein overexpression and MsrA function in mammals, similar studies will be
conducted in transgenic α-synuclein mice on an MsrA−/− background.
Acknowledgments
This work was supported by the Kansas EPSCOR/National Science Foundation and the National Institute of Aging,
AG027363.
References
Baba M, Nakajo S, Tu PH, et al. Aggregation of alpha-synuclein in Lewy bodies of sporadic
Parkinson’s disease and dementia with Lewy bodies. American Journal of Pathology. 1998;
152:879–884. [PubMed: 9546347]
Berke SJ, Paulson HL. Protein aggregation and the ubiquitin proteasome pathway: gaining the upper
hand on neurodegeneration. Current Opinion in Genetics and Development. 2003; 13:253–261.
[PubMed: 12787787]
Bigelow DJ, Squier TC. Redox modulation of cellular signaling and metabolism through reversible
oxidation of methionine sensors in calcium regulatory proteins. Biochimica et Biophysica Acta.
2005; 1703:121–134. [PubMed: 15680220]
Brandis KA, Holmes IF, England SJ, Sharma N, Kukreja L, DebBurman SK. Alpha-synuclein fission
yeast model: Concentration-dependent aggregation without plasma membrane localization or
toxicity. J Mol Neurosci. 2006; 28:179–191. [PubMed: 16679557]
Bussell R Jr, Eliezer D. A structural and functional role for 11-mer repeats in alpha-synuclein and
other exchangeable lipid binding proteins. J Mol Biol. 2003; 329:763–778. [PubMed: 12787676]
Chao CC, Ma YS, Stadtman ER. Modification of protein surface hydrophobicity and methionine
oxidation by oxidative systems. Proceedings of the National Academy of Sciences of the United
States of America. 1997; 94:2969–2974. [PubMed: 9096330]
Chen L, Feany MB. Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation
in a Drosophila model of Parkinson disease. Nature Neuroscience. 2005; 8:657–663.
Chen Q, Thorpe J, Ding Q, El-Amouri IS, Keller JN. Proteasome synthesis and assembly are required
for survival during stationary phase. Free Radical Biology and Medicine. 2004; 37:859–868.
[PubMed: 15304258]
Oien et al. Page 8













Chen Q, Thorpe J, Keller JN. Alpha-synuclein alters proteasome function, protein synthesis, and
stationary phase viability. J Biol Chem. 2005; 280:30009–30017. [PubMed: 15941712]
Fink AL. The aggregation and fibrillation of alpha-synuclein. Acc Chem Res. 2006; 39:628–634.
[PubMed: 16981679]
Fujiwara H, Hasegawa M, Dohmae N, et al. Alpha-synuclein is phosphorylated in synucleinopathy
lesions. Nature Cell Biology. 2002; 4:160–164.
Giasson BI, Duda JE, Murray IV, et al. Oxidative damage linked to neurodegeneration by selective
alpha-synuclein nitration in synucleinopathy lesions. Science. 2000; 290:985–989. [PubMed:
11062131]
Giorgi FS, Bandettini di Poggio A, Battaglia G, et al. A short overview on the role of alpha-synuclein
and proteasome in experimental models of Parkinson’s disease. J Neural Transm Suppl. 2006;
70:105–109. [PubMed: 17017516]
Hawe A, Sutter M, Jiskoot W. Extrinsic fluorescent dyes as tools for protein characterization.
Pharmaceutical Research. 2008; 25:1487–1499. [PubMed: 18172579]
Hsu LJ, Sagara Y, Arroyo A, et al. Alpha-synuclein promotes mitochondrial deficit and oxidative
stress. American Journal of Pathology. 2000; 157:401–410. [PubMed: 10934145]
Ishii A, Nonaka T, Taniguchi S, et al. Casein kinase 2 is the major enzyme in brain that phosphorylates
ser129 of human alpha-synuclein: Implication for alpha-synucleinopathies. FEBS Letters. 2007;
581:4711–4717. [PubMed: 17868672]
Jo E, Fuller N, Rand RP, St George-Hyslop P, Fraser PE. Defective membrane interactions of familial
Parkinson’s disease mutant a30p alpha-synuclein. J Mol Biol. 2002; 315:799–807. [PubMed:
11812148]
Kanayama A, Inoue J, Sugita-Konishi Y, Shimizu M, Miyamoto Y. Oxidation of Ikappa Balpha at
methionine 45 is one cause of taurine chloramine-induced inhibition of NF-kappa B activation. J
Biol Chem. 2002; 277:24049–24056. [PubMed: 11983684]
Kruger R, Kuhn W, Muller T, et al. Ala30pro mutation in the gene encoding alpha-synuclein in
Parkinson’s disease. Nature Genetics. 1998; 18:106–108. [PubMed: 9462735]
Lee HJ, Choi C, Lee SJ. Membrane-bound alpha-synuclein has a high aggregation propensity and the
ability to seed the aggregation of the cytosolic form. J Biol Chem. 2002; 277:671–678. [PubMed:
11679584]
Lindersson E, Beedholm R, Hojrup P, et al. Proteasomal inhibition by alpha-synuclein filaments and
oligomers. J Biol Chem. 2004; 279:12924–12934. [PubMed: 14711827]
Liu F, Hindupur J, Nguyen JL, et al. Methionine sulfoxide reductase a protects dopaminergic cells
from parkinson’s disease-related insults. Free Radical Biology and Medicine. 2008; 45:242–255.
[PubMed: 18456002]
Lucking CB, Brice A. Alpha-synuclein and Parkinson’s disease. Cellular and Molecular Life Sciences.
2000; 57:1894–1908. [PubMed: 11215516]
Midwinter RG, Cheah FC, Moskovitz J, Vissers MC, Winterbourn CC. Ikappab is a sensitive target for
oxidation by cell-permeable chloramines: Inhibition of NF-kappaB activity by glycine chloramine
through methionine oxidation. Biochemical Journal. 2006; 396:71–78. [PubMed: 16405428]
Mohri M, Reinach PS, Kanayama A, et al. Suppression of the TNFalpha-induced increase in IL-1alpha
expression by hypochlorite in human corneal epithelial cells. Investigative Ophthalmology and
Visual Science. 2002; 43:3190–3195. [PubMed: 12356823]
Moskovitz J. Methionine sulfoxide reductases: Ubiquitous enzymes involved in antioxidant defense,
protein regulation, and prevention of aging-associated diseases. Biochimica et Biophysica Acta.
2005; 1703:213–219. [PubMed: 15680229]
Moskovitz J. Prolonged selenium-deficient diet in MsrA knockout mice causes enhanced oxidative
modification to proteins and affects the levels of antioxidant enzymes in a tissue-specific manner.
Free Radical Research. 2007; 41:162–171. [PubMed: 17364942]
Moskovitz J, Bar-Noy S, Williams WM, Requena J, Berlett BS, Stadtman ER. Methionine sulfoxide
reductase (MsrA) is a regulator of antioxidant defense and lifespan in mammals. Proceedings of
the National Academy of Sciences of the United States of America. 2001; 98:12920–12925.
[PubMed: 11606777]
Oien et al. Page 9













Moskovitz J, Berlett BS, Poston JM, Stadtman ER. The yeast peptide-methionine sulfoxide reductase
functions as an antioxidant in vivo. Proceedings of the National Academy of Sciences of the
United States of America. 1997; 94:9585–9589. [PubMed: 9275166]
Moskovitz J, Stadtman ER. Selenium-deficient diet enhances protein oxidation and affects methionine
sulfoxide reductase (MsrB) protein level in certain mouse tissues. Proceedings of the National
Academy of Sciences of the United States of America. 2003; 100:7486–7490. [PubMed:
12792026]
Munishkina LA, Henriques J, Uversky VN, Fink AL. Role of protein–water interactions and
electrostatics in alpha-synuclein fibril formation. Biochemistry. 2004; 43:3289–3300. [PubMed:
15023080]
Oien D, Moskovitz J. Protein-carbonyl accumulation in the non-replicative senescence of the
methionine sulfoxide reductase a (MsrA) knockout yeast strain. Amino Acids. 2007; 32:603–606.
[PubMed: 17077964]
Oien DB, Moskovitz J. Substrates of the methionine sulfoxide reductase system and their
physiological relevance. Current Topics in Developmental Biology. 2008; 80:93–133. [PubMed:
17950373]
Oien DB, Osterhaus GL, Latif SA, et al. Msra knockout mouse exhibits abnormal behavior and brain
dopamine levels. Free Radical Biology and Medicine. 2008; 45:193–200. [PubMed: 18466776]
Olry A, Boschi-Muller S, Marraud M, Sanglier-Cianferani S, Van Dorsselear A, Branlant G.
Characterization of the methionine sulfoxide reductase activities of PILB, a probable virulence
factor from Neisseria meningitidis. J Biol Chem. 2002; 277:12016–12022. [PubMed: 11812798]
Ostrerova-Golts N, Petrucelli L, Hardy J, Lee JM, Farer M, Wolozin B. The a53t alpha-synuclein
mutation increases iron-dependent aggregation and toxicity. J Neurosci. 2000; 20:6048–6054.
[PubMed: 10934254]
Outeiro TF, Lindquist S. Yeast cells provide insight into alpha-synuclein biology and pathobiology.
Science. 2003; 302:1772–1775. [PubMed: 14657500]
Pal R, Oien DB, Ersen FY, Moskovitz J. Elevated levels of brain-pathologies associated with
neurodegenerative diseases in the methionine sulfoxide reductase a knockout mouse. Experimental
Brain Research. 2007; 180:765–774.
Paleologou KE, Schmid AW, Rospigliosi CC, et al. Phosphorylation at ser-129 but not the
phosphomimics s129e/d inhibits the fibrillation of alpha-synuclein. J Biol Chem. 2008;
283:16895–16905. [PubMed: 18343814]
Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in
families with Parkinson’s disease. Science. 1997; 276:2045–2047. [PubMed: 9197268]
Sawada H, Kohno R, Kihara T, et al. Proteasome mediates dopaminergic neuronal degeneration, and
its inhibition causes alpha-synuclein inclusions. J Biol Chem. 2004; 279:10710–10719. [PubMed:
14672949]
Sharma N, Brandis KA, Herrera SK, et al. Alpha-synuclein budding yeast model: Toxicity enhanced
by impaired proteasome and oxidative stress. J Mol Neurosci. 2006; 28:161–178. [PubMed:
16679556]
Singleton AB, Farrer M, Johnson J, et al. Alpha-synuclein locus triplication causes Parkinson’s
disease. Science. 2003; 302:841. [PubMed: 14593171]
Smith WW, Margolis RL, Li X, et al. Alpha-synuclein phosphorylation enhances eosinophilic
cytoplasmic inclusion formation in sh-sy5y cells. J Neurosci. 2005; 25:5544–5552. [PubMed:
15944382]
Snyder H, Mensah K, Hsu C, et al. Beta-synuclein reduces proteasomal inhibition by alpha-synuclein
but not gamma-synuclein. J Biol Chem. 2005; 280:7562–7569. [PubMed: 15591046]
Stadtman ER, Berlett BS. Reactive oxygen-mediated protein oxidation in aging and disease. Drug
Metabolism Reviews. 1998; 30:225–243. [PubMed: 9606602]
Starke-Reed PE, Oliver CN. Protein oxidation and proteolysis during aging and oxidative stress.
Archives of Biochemistry and Biophysics. 1989; 275:559–567. [PubMed: 2574564]
Takeda A, Mallory M, Sundsmo M, Honer W, Hansen L, Masliah E. Abnormal accumulation of
NACP/alpha-synuclein in neurodegenerative disorders. American Journal of Pathology. 1998;
152:367–372. [PubMed: 9466562]
Oien et al. Page 10













Vekrellis K, Rideout HJ, Stefanis L. Neurobiology of alpha-synuclein. Molecular Neurobiology. 2004;
30:1–21. [PubMed: 15247485]
Willingham S, Outeiro TF, DeVit MJ, Lindquist SL, Muchowski PJ. Yeast genes that enhance the
toxicity of a mutant huntingtin fragment or alpha-synuclein. Science. 2003; 302:1769–1772.
[PubMed: 14657499]
Yamin G, Glaser CB, Uversky VN, Fink AL. Certain metals trigger fibrillation of methionine-oxidized
alpha-synuclein. J Biol Chem. 2003; 278:27630–27635. [PubMed: 12754258]
Oien et al. Page 11














Presence of α-synuclein over time isolated from msrA-KO and WT yeast cells. Soluble α-
synucleins (WT-α-syn, A30P, A53T) were isolated from cells at specified time points
during α-synuclein protein induction. Equal amounts of cells were taken from each culture
and α-synuclein proteins were isolated by resin from the corresponding extracts. a The α-
synuclein proteins were detected by Western blotting using antibodies specific to the 6His
tag. Left side: α-synuclein from WT yeast cells. Right side: α-synuclein from msrA-KO
yeast cells. Horizontal axis: time from start of α-synuclein induction period (2, 3, 4, 8, and
24 h). b Densitometry analysis performed on the protein bands shown in a. To compare
between the types of synuclein expressed and cells, the pattern of resistance to degradation
over time was demonstrated as a percent ratio of the protein densitometry for each time
point relative to the densitometry value of the 2-h point level (represented 100% expression
level)
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Total protein degradation and synthesis in msrA-KO and WT yeast cells. a Total
degradation of soluble cytosolic proteins. Soluble protein fraction was precipitated by TCA
following pulse-chase labeling with [35S]Met during α-synuclein protein induction. Values
represent the percent of counts per minute of the TCA-soluble material divided by the total
counts per minute values (TCA-soluble material plus precipitated TCA pellet at specified
time points). Black bars represent WT yeast cells; white bars represent msrA-KO yeast cells.
Top left: cells expressing sham vector. Bottom Left: cells expressing α-synuclein (WT-α-
syn). Top right: cells expressing A30P α-synuclein. Bottom right: cells expressing A53T α-
synuclein. b For quantification of protein synthesis, the radioactivity (counts per minute) in
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the TCA-insoluble material was measured following labeling with [35S]Met. Black bars
represent WT; white bars represent msrA-KO yeast cells. The annotation for the type of
expression (vector or α-synuclein) is the same as in aError bars represent standard error of
three experiments. *P<0.05
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Detection of fibrils present in msrA-KO and WT yeast cells by Thioflavin T staining. Yeast
cells were stained with Thioflavin T after α-synuclein (WT-α-syn, A30P, A53T) induction
of expression and transferring equal aliquots of cells into a 96-well plate. Cells were
detected by phase-contrast microscopy and staining was detected with epifluorescence, both
using a Nikon 40X objective of 1.3 N. A. and a standard DAPI/FitC/ TxRed B filter set and
dichroic (Brightline filters, Semrock). a Representative images of cells collected by IN Cell
Analyzer (GE Healthcare). For visualization, Image J software was used to make cells
appear as red, fibrils appear as green, and to make an overlay image. b Quantification of
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stained cells per number of cells present determined by IN Cell Analyzer provided software.
Automated image segmentation was achieved independently on each image channel using
the Otsu “global” method of thresholding. Black bars represent WT yeast cells; white bars
represent msrA-KO yeast cells. Error bars represent standard deviation of six experiments.
*P<0.0001
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Phosphorylation of α-synuclein isolated from msrA-KO and WT yeast cells. a Each yeast
strain expressing each α-synuclein type was induced and then incubated in medium
containing ortho-[32P] phosphoric acid. Expressed α-synuclein proteins (WT-α-syn, A30P,
A53T) were isolated by resin binding and phosphorylation was detected by measuring
counts per minute. Values represent percentage of counts per minute value relative to WT-
α-syn counts per minute value in WT yeast cells. Black bars represent WT yeast cells; white
bars represent msrA-KO yeast cells. Error bars represent standard error of four experiments.
*P<0.001; **P<0.05. b A representative gel stained with GelCode Blue Stain reagent. Left
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lane: SeeBlue Plus2 protein standard (Invitrogen). Right lane: typical separation of pure
commercial recombinant human α-synuclein proteins (WT-α-syn shown as a representative
α-synuclein; arrow indicates the band corresponding to α-synuclein). c Pure commercial
recombinant human α-synuclein proteins (WT-α-syn, A30P, A53T) were exposed to H2O2
overnight (Oxidized). Oxidant was removed by catalase and Msr enzymes were added where
indicated (PilB, MsrA). The removal of oxidants was verified by adding α-synuclein after
oxidants were removed and served as the nonoxidized form of α-synuclein (Control). All
samples were phosphorylated with [γ-32P]-ATP and casein kinase 2. Equal amounts of α-
synuclein proteins were subjected to an SDS-gel electrophoresis and the gel was exposed to
X-ray film, followed by developing for visualization
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